Ophthotech Corp. Form 4
October 03, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> GUYER DAVID R

(Last) (First) (Middle)

C/O OPHTHOTECH CORPORATION, ONE PENN PLAZA, 19TH FLOOR

(Street) 4. If Amendment, D

Filed(Month/Day/Year)

2. Issuer Name **and** Ticker or Trading Symbol

Ophthotech Corp. [OPHT]

3. Date of Earliest Transaction (Month/Day/Year)

10/01/2014

4. If Amendment, Date Original

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

OMB

Number:

Expires:

response...

Estimated average

burden hours per

OMB APPROVAL

3235-0287

January 31,

2005

0.5

X Director _____ 10% Owner _X_ Officer (give title _____ Other (specify below)

6. Individual or Joint/Group Filing(Check

Chief Executive Officer

Applicable Line)

X Form filed by One Reporting Person ____ Form filed by More than One Reporting

Person

NEW YORK, NY 10119

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securit on(A) or Di (Instr. 3,	sposed	of (D)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common	10/01/2014		Code V M(1)	Amount 12,277	(A) or (D)	Price \$	Reported Transaction(s) (Instr. 3 and 4) 12,277	(Instr. 4)		
Stock Common Stock	10/01/2014		S <u>(1)</u>	8,355	D	10.03 \$ 37.12 (2)		D		
Common Stock	10/01/2014		S <u>(1)</u>	3,572	D	\$ 37.61 (3)	300	D		
Common Stock	10/01/2014		S <u>(1)</u>	300	D	\$ 38.65	0	D		

Edgar Filing: Ophthotech Corp. - Form 4

(4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right To Buy)	\$ 10.03	10/01/2014		M <u>(1)</u>	12,227	<u>(5)</u>	04/25/2023	Common Stock	12,227

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

GUYER DAVID R C/O OPHTHOTECH CORPORATION ONE PENN PLAZA, 19TH FLOOR NEW YORK, NY 10119

X

Chief Executive Officer

Relationships

Signatures

/s/ Justin Vogel, as Attorney-in-Fact for David
Guyer
10/03/2014

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2013.
- (2) These shares were disposed of in multiple transactions on October 1, 2014 at actual sales prices ranging from \$36.45 to \$37.43 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request

Reporting Owners 2

Edgar Filing: Ophthotech Corp. - Form 4

by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

- These shares were disposed of in multiple transactions on October 1, 2014 at actual sales prices ranging from \$37.45 to \$38.13 per share.

 The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- These shares were disposed of in multiple transactions on October 1, 2014 at actual sales prices ranging from \$38.60 to \$38.74 per share.

 The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (5) This option was granted on April 26, 2013 and vests as to 1/48 of the shares underlying such option each month until April 2018. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.